|1.||Chung, Jing-Gung: 9 articles (11/2015 - 11/2009)|
|2.||Yang, Jai-Sing: 6 articles (03/2013 - 11/2009)|
|3.||Lin, Jen-Jyh: 5 articles (11/2015 - 03/2012)|
|4.||Lu, Chi-Cheng: 5 articles (11/2013 - 11/2009)|
|5.||Chiang, Jo-Hua: 5 articles (11/2013 - 11/2009)|
|6.||Lin, Jing-Pin: 4 articles (11/2015 - 11/2009)|
|7.||Lin, Chin-Chung: 3 articles (11/2013 - 05/2012)|
|8.||Kuo, Chao-Lin: 3 articles (11/2013 - 05/2010)|
|9.||Fan, Ming-Jen: 3 articles (03/2013 - 11/2009)|
|10.||Tang, Nou-Ying: 2 articles (11/2015 - 03/2012)|
12/01/1990 - "Our studies of tumor-induced M phi-mediated dysfunction used M phi subsets which were defined by their Mac-1, Mac-2, and Mac-3 surface markers. "
11/01/2007 - "Within these CD45(+) cell populations, preferential accumulation in the tumor was observed of cells expressing Sca-1, c-kit, NK1.1, Thy1.2, CD14, Mac-3 and/or CD11c. "
11/01/2003 - "Spleen cells expressing CD3, CD4, CD8, CD19, Mac-3, and CD44 were all susceptible to tumor-induced apoptosis. "
11/15/1984 - "Firstly, ESb cells are shown to express the macrophage differentiation antigen Mac-1 which was not found on Eb cells or on any other tumor cells tested except the macrophage tumor line Pu5. "
02/15/1992 - "Macrophages stimulated by receptor-ligand interactions exhibit differences in cell-cycle kinetics during tumor growth: stimulation at Mac-1 and Mac-3 receptors alters DNA synthesis."
11/01/2015 - "DATS increases the surface markers of CD11b and Mac-3 in leukemia mice but only promoted CD3 in normal mice. "
09/01/2013 - "Furthermore, EGCG increased the percentage of cluster of differentiation 3 (CD3) (T-cell), cluster of differentiation 19 (CD19) (B-cell) and Macrophage-3 antigen (Mac-3) (macrophage) but reduced the percentage of CD11b (monocyte) cell surface markers in EGCG-treated groups as compared with the untreated leukemia group. "
03/01/2012 - "Moreover, ABM increased the levels of CD3 and CD19 but decreased the levels of Mac-3 and CD11b in leukemia mice. "
05/01/2010 - "The SLE treatment decreases surface markers of CD3 and Mac-3 in normal and leukemia mice but promoted the cell markers of CD19 and CD11b in normal mice and CD11b in leukemia mice indicating that the precursors of T cells was inhibited and B cells and macrophage were promoted. "
11/01/2009 - "Then we investigated in vivo effects of BITC on murine leukemia WEHI-3 cells and the results indicated that BITC decreased the weights of liver and spleen and it also decreased the percentage of CD11b and Mac-3 markers, indicating that the differentiation of the precursor of macrophage and B cells was inhibited. "
|3.||Atherosclerotic Plaque (Atheroma)
02/01/2013 - "Brachiocephalic atherosclerotic plaque area [(4.597 ± 1.260)×10(3) µm(2) vs. (0.075 ± 0.030)×10(3) µm(2)], lipid deposition [(47.23 ± 2.64)% vs. (9.67 ± 1.75)%], Mac-3 positive area [(19.15 ± 3.51)% vs. (1.72 ± 0.16)%], α-smooth muscle actin [(5.54 ± 1.17)% vs. (2.13 ± 0.41)%] and collagen content [(4.27 ± 0.74)% vs. (0.43 ± 0.09)%] were all significantly larger/higher in diabetic LDLr-/- mice than in the control group (all P < 0.01). "
08/01/2011 - "Upregulated TGF-β(1) and Mac-3 expression in the aortic atherosclerotic lesions in apoE-/- mice fed with high fat diet could also be significantly reduced by rosuvastatin (all P < 0.01), suggesting reduce inflammatory responses in the atherosclerotic lesion and stable atherosclerotic plaque post rosuvastatin treatment. "
05/13/2005 - "In apolipoprotein E-knockout mice on a high cholesterol diet, BM-derived cells expressing Mac-3 in the atheromatous plaques were also positive for HDC. "
01/01/2012 - "Staining for Mac-3 (macrophage-3) and α-SMA (α-smooth muscle actin) revealed extensive infiltration of macrophages and medial hypertrophy of large pulmonary vessels with complete occlusion of small arteries respectively. "
02/01/2011 - "SMA and Mac-3 staining demonstrated hypertrophy of pulmonary arteries with occlusion of precapillary vessels and extensive infiltration of macrophages, respectively. "
|5.||Body Weight (Weight, Body)
03/01/1985 - "We conclude that (a) tissues from MAC-2 and MAC-3 fetuses do not grow and thus need not be sampled at autopsy, (b) maceration degree and body weight can be used to predict the growth probability in the other categories, (c) tissue samples can be taken during daylight hours, since autopsy interval does not influence successful growth provided the fetus is refrigerated at 4 degrees C, (d) all of the above conclusions have cost-efficiency implications for cytogenetic laboratories."
05/01/2012 - "The results indicated that (1) As₂O₃ alone or As₂O₃ combined with ATRA promoted the total survival rate of leukemia mice and these effects are dose-dependent; (2) As₂O₃ did not affect the body weight but decreased the spleen weight; however, it did not affect liver weight; (3) As₂O₃ alone or As₂O₃ combined with ATRA increased the levels of CD3 and CD19, indicating that the differentiation of T and B cells were promoted; and (4) As₂O₃ alone or As₂O₃ combined with ATRA did not change the levels of Mac-3 and CD11b markers, indicating that the differentiation of the precursor of macrophage were not inhibited. "
|1.||Integrin alpha4beta1 (VLA-4)
|3.||Vascular Cell Adhesion Molecule-1 (Vascular Cell Adhesion Molecule 1)
|4.||Intercellular Adhesion Molecule-1 (Intercellular Adhesion Molecule 1)
|5.||Proto-Oncogene Proteins c-fos (FRAs)
|6.||Lymphocyte Function-Associated Antigen-1 (LFA-1)
|7.||DNA (Deoxyribonucleic Acid)
|10.||Apolipoproteins E (ApoE)